Central European Journal of Medicine

, Volume 3, Issue 1, pp 71–76 | Cite as

No effect of human chorionic gonadotropin treatment due to threatened abortion in early pregnancy for birth outcomes

  • Andrew E. Czeizel
  • István Dudás
  • János Gidai
  • Erzsébet Horváth-Puhó
Research Article


Human chorionic gonadotropin (HCG) is used parenterally for treatment of threatened abortions and repeated spontaneous abortion in pregnant women. No controlled epidemiological studies of preterm birth and low birthweight newborns in pregnant women with HCG treatment have been published while the results of animal investigations were controversial. The data of 97 pregnant women with HCG treatment in the second and third months of pregnancy due to threatened abortion and/or previous spontaneous abortion(s) was compared with the data of other 38,054 pregnant women in the population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities. There was no difference in mean gestational age at delivery and birth weight, in addition the rate of preterm birth and low birthweight newborns. Parenteral HCG treatment in the early pregnancy due to threatened abortion did not associate with a higher risk for preterm births or low birthweight newborns. However, a higher occurrence of gestational diabetes was found in pregnant women with HCG treatment and there was a slight male excess among newborn infants (p=0.06).


Human chorionic gonadotropin Pregnancy Threatened abortion Preterm birth Low birthweight newborns 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Conlson C.J., Molecular mechanism of drug action. Taylor and Francis, London. 1988Google Scholar
  2. [2]
    Sakai N., Endo A., Potential teratogenicity of gonadotropin treatment for ovulation induction in the mouse offspring. Teratology, 1987, 36, 229–233PubMedCrossRefGoogle Scholar
  3. [3]
    Bussi R., Ciampolillo C., Commotto L., Komatsu S., Maraschin R., Reproductive and developmental toxicity studies of SJ-0021 (v-hFSH). Yakuri to Chiryo., 1995, 23, 1953–1997 cit. Shepard TH, and Lemire RJ, 2004.Google Scholar
  4. [4]
    Hultquist G.T., Engfeldt B., Growth of rat fetuses produced experimentally by means of administration of hormones to the mother during pregnancy. Acta Endocrinol (Kbh), 1949, 3, 365–376Google Scholar
  5. [5]
    Hack M., Brish M., Serr D., Insler V., Lunenfeld B., Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after gonadotropin therapy. J.A.M.A., 1970, 211, 791–793PubMedCrossRefGoogle Scholar
  6. [6]
    Ben-Rafael Z., Mashiach S., Velsner G., Farine D., Lunenfeld B., Serr D.M., Spontaneous pregnancy and its outcome after human menopausal gonadotropin/human chorionic gonadotropin-induced pregnancy. Fertil. Steril., 1981, 36, 560–566PubMedGoogle Scholar
  7. [7]
    Ben-Rafael Z., Dor J., Mashiach S., Blankstein J., Lunenfeld B., Serr D.M., Abortion rate in pregnancies following ovulation induced by human menopausal gonadotropin/human chorionic gonadotropin. Fertil. Steril., 1983, 39, 157–162PubMedGoogle Scholar
  8. [8]
    Caspi E., Ronen J., Schreyer P., Goldberg M.D., The outcome of pregnancy after gonadotrophin therapy. Br. J. Obstet. Gynecol., 1996, 83, 967–973Google Scholar
  9. [9]
    Shepard T.H., Lemire R.J., Catalog of Teratogenic Agents. 11th ed. John Hopkins. Univ. Press, Baltimore, 2004Google Scholar
  10. [10]
    Czeizel A.E., Rockenbauer M., Siffel Cs., Varga E., Description and mission evaluation of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980–1996. Teratology, 2001, 63, 176–185PubMedCrossRefGoogle Scholar
  11. [11]
    Czeizel A.E., The first 25 years of the Hungarian Congenital Abnormality Registry. Teratology, 1997, 55, 299–305PubMedCrossRefGoogle Scholar
  12. [12]
    Czeizel A.E., Petik D., Vargha P., Validation studies of drug exposures in pregnant women. Pharmacoepidemiol. Drug Safety, 2003, 12, 409–406CrossRefGoogle Scholar
  13. [13]
    Czeizel A.E., Petik D., Puho E., Smoking and alcohol drinking during pregnancy: the validity of retrospective maternal self-reported information. Cent. Eur. J. Publ. Hlth., 2004, 12, 179–193Google Scholar
  14. [14]
    Czeizel A.E., Puhó E., Maternal use of nutritional supplements during the first month of pregnancy and decreased risk of Down’s syndrome: casecontrol study. Nutrition, 2005, 21, 698–704PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Andrew E. Czeizel
    • 1
  • István Dudás
    • 1
  • János Gidai
    • 1
  • Erzsébet Horváth-Puhó
    • 1
  1. 1.Foundation for the Community Control of Hereditary DiseasesBudapestHungary

Personalised recommendations